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Abstract
Background: There are recognised gaps between evidence and practice in general practice, a setting which provides
particular challenges for implementation. We earlier screened clinical guideline recommendations to derive a set of ‘high
impact’ indicators based upon criteria including potential for significant patient benefit, scope for improved practice and
amenability to measurement using routinely collected data. We aim to evaluate the effectiveness and cost-
effectiveness of a multifaceted, adaptable intervention package to implement four targeted, high impact
recommendations in general practice.
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Methods/design: The research programme Action to Support Practice Implement Research Evidence (ASPIRE) includes
a pair of pragmatic cluster-randomised trials which use a balanced incomplete block design. Clusters are general practices
in West Yorkshire, United Kingdom (UK), recruited using an ‘opt-out’ recruitment process. The intervention
package adapted to each recommendation includes combinations of audit and feedback, educational outreach visits
and computerised prompts with embedded behaviour change techniques selected on the basis of identified needs
and barriers to change. In trial 1, practices are randomised to adapted interventions targeting either diabetes control or
risky prescribing and those in trial 2 to adapted interventions targeting either blood pressure control in patients at risk
of cardiovascular events or anticoagulation in atrial fibrillation. The respective primary endpoints comprise achievement
of all recommended target levels of haemoglobin A1c (HbA1c), blood pressure and cholesterol in patients with type 2
diabetes, a composite indicator of risky prescribing, achievement of recommended blood pressure targets for specific
patient groups and anticoagulation prescribing in patients with atrial fibrillation. We are also randomising practices to a
fifth, non-intervention control group to further assess Hawthorne effects. Outcomes will be assessed using routinely
collected data extracted 1 year after randomisation. Economic modelling will estimate intervention cost-effectiveness. A
process evaluation involving eight non-trial practices will examine intervention delivery, mechanisms of action and
unintended consequences.
Discussion: ASPIRE will provide ‘real-world’ evidence about the effects, cost-effectiveness and delivery of adapted
intervention packages targeting high impact recommendations. By implementing our adaptable intervention package
across four distinct clinical topics, and using ‘opt-out’ recruitment, our findings will provide evidence of wider
generalisability.
Trial registration: ISRCTN91989345
Keywords: Primary care, Implementation, Cluster-randomised trial, Clinical guidelines, Diabetes, Prescribing, Atrial
fibrillation
Background
Clinical research can only benefit patient and popula-
tion health if findings are incorporated into routine
care. There are widely recognised failures to introduce
effective new clinical practices quickly enough, con-
sistently use those already proven to be effective or
stop those found to be ineffective or even harmful.
The gap between evidence and practice is an import-
ant problem for policy-makers, healthcare systems
and research funders because it limits the health, so-
cial and economic impacts of clinical research [1].
Dissemination of best practice is necessary but sel-
dom sufficient by itself to ensure implementation.
The context of general practice in the United Kingdom
(UK) presents particular implementation challenges—-
given the limited practice organisational capacity, the
increasing complexity of care and the dispersed and
independent nature of practices. Many implementa-
tion studies focus on one condition (e.g. depression,
back pain). This limits generalisability; it is uncertain
how an intervention developed for one clinical condi-
tion will work for another [2, 3]. In 2012, we identi-
fied 107 clinical guidelines relevant to general
practice produced by the National Institute for Health
and Care Excellence (NICE) [4]. It is impracticable
and inefficient to invent an implementation strategy
for every new guideline. Implementation strategies are
required which can be adapted to a range of targeted
problems and sustainably integrated into available primary
care systems and resources [5].
Action to Support Practices Implement Research Evi-
dence (ASPIRE) is a research programme that aims to
develop and evaluate an adaptable intervention package to
target implementation of ‘high impact’ clinical practice
recommendations in general practice. ASPIRE comprises
five, sequential work packages:
1. Screening of NICE guidelines and associated quality
standards to derive a set of ‘high impact’ indicators
based on burden of illness, potential for significant
patient benefit from improved practice, likelihood of
cost savings without patient harm and feasibility of
measuring change using routinely collected data [4].
2. Cross-sectional analysis of patient data to identify
high impact recommendations with greatest scope
for improvement (low adherence) and explore
variations in adherence.
3. Interviews with primary care professionals to
explore barriers to and enablers of adherence to
selected high impact recommendations, matching
of behaviour change techniques to identified
barriers and enablers and development of an adaptable
intervention package (based on audit and feedback,
outreach educational visits and computerised prompts).
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4. Evaluation of the effectiveness and cost-effectiveness
of the adapted intervention package in targeting the
implementation of high impact recommendations.
5. Conduct of a parallel process evaluation to examine
intervention delivery, mechanisms of action and
unintended consequences.
This protocol paper describes the randomised evalu-
ation and summarises the process evaluation.
Methods/design
Study design and setting
We are conducting a pair of pragmatic cluster-
randomised trials with general practices as the unit of al-
location. Cluster randomisation was chosen because the
intervention is delivered at the practice level and aims to
change clinical practice of the whole practice team. Bal-
anced incomplete block designs equalise Hawthorne ef-
fects whilst maximising power and efficiency [6, 7] and
also reduce the risk of overburdening practices through
exposure to more than one intervention. In trial 1,
practices will be randomised to adapted intervention
packages targeting either diabetes control or risky pre-
scribing. In trial 2, practices will be randomised to adapted
intervention packages targeting either blood pressure con-
trol in patients at high risk of cardiovascular events or
anticoagulation in atrial fibrillation. The balanced incom-
plete block design has two treatment arms per trial.
Within both trials, all intervention packages were assumed
to be independent in terms of their outcomes and each
treatment arm will therefore be used as the control arm
for the other treatment arm in the same trial (Fig. 1 and
Additional file 1 detail a full CONSORT checklist). We are
also including a fifth, non-intervention control group to
further assess Hawthorne effects. Practices allocated to
this arm will not receive any of the ASPIRE interventions,
but we will examine outcomes via the same routinely col-
lected data.
The study is set within West Yorkshire, which covers a
socioeconomically and ethnically diverse population of ap-
proximately 2.2 million residents [8]. Around 330 general
practices are organised within 10 clinical commissioning
groups (CCGs), which have roles including the purchasing
of specialist services and improving quality of primary care.
Participants
General practices are eligible if they used the SystmOne
computerised clinical system (TPP, http://www.tpp-
1
Excluded (n=X):
Participated earlier in programme, therefore not eligible (n=X); Closed / not contactable (n=X)
Excluded (n=X):
Declined participation (n=X); Practice closed / merged (n=X); Issues with data availability due 
to CCG boundary (n=X); Practice recruited to process evaluation (n=X)
Allocated to trial 1 (n=X) Allocated to trial 2 (n=X) Allocated to non-intervention control (n=X)
Lost to follow-up (give reasons) n/a
Discontinued intervention (give 
reasons) n/a
Lost to follow-up (give reasons) n/a
Discontinued intervention (give 
reasons) n/a
Lost to follow-up (give reasons) n/a
Analysed n/a
Excluded from analysis (give 
reasons) n/a
Analysed n/a
Excluded from analysis (give reasons) n/a
Randomised (n=X)
Invited to participate (n=X)
Analysed n/a
Excluded from analysis (give 
reasons) n/a
Clusters assessed for eligibility (general practices in West Yorkshire (10 CCGs) that use 
SystmOne) (n=X)
Diabetes 
outcomes 
(n=X)
Hyper-
tension (n=X)
Atrial 
fibrillation 
(n=X)
Risky 
prescribing 
(n=X)
Fig. 1 CONSORT 2010 checklist of information to include when reporting a cluster randomised trial
Willis et al. Implementation Science  (2016) 11:25 Page 3 of 11
uk.com/). Approximately two thirds of West Yorkshire
practices use SystmOne. The use of a single system sim-
plifies the process of data extraction and of implement-
ing software support. We will exclude practices which
had been involved in earlier stages of intervention devel-
opment and piloting. We will also exclude from trial 2
practices in one CCG involved in a concurrent initiative
addressing anticoagulation in atrial fibrillation.
Recruitment and consent
Following consultations with our Programme Steering
Group, our Public and Patient Involvement Panel and all
10 CCGs, we will use an ‘opt-out’ approach to recruit and
consent general practices. Apart from facilitating the
recruitment process, we judge that opt-out recruitment
will enhance pragmatism and hence generalisability by
resembling recruitment processes typically used by rou-
tine quality improvement initiatives [9]. We will send all
eligible practices an invitation and information sheet via
email. This outlines the purpose of the trial and what
involvement entails and states that practices will be in-
cluded unless they indicate otherwise. We will follow this
with a duplicate pack (including a Freepost return enve-
lope to return the opt-out notification) sent via recorded
postal delivery. After 2 weeks, we will send reminders by
both email and recorded postal delivery to all non-
responding practices. Four weeks post-initial invitation,
we will consider all practices which have not opted-out to
have consented to participate. Patient-level consent is not
required as all patient-level data are anonymised.
Intervention
We broadly conceptualise the implementation intervention
as comprising a range of behaviour change techniques (e.g.
social comparison, information on health consequences,
action planning). These will be embedded within a package
based around three delivery mechanisms that possess a
known evidence base and are increasingly central to routine
implementation activities [7]: audit and feedback [7, 10],
educational outreach visits [7, 11] and computerised
prompts [7, 12]. We have further developed the pack-
ages iteratively through a series of exchanges with our
professional and patient advisory groups and piloting in
five general practices.
Following earlier work and consultations with pro-
fessional and patient advisory groups, we decided to
target the implementation of four high impact
indicators:
 Control of HbA1c, blood pressure and cholesterol in
type 2 diabetes [13, 14]
 Risky prescribing, largely focusing on avoiding
adverse effects of non-steroidal anti-inflammatory
drugs (NSAIDs) and anti-platelet drugs [15]
 Control of blood pressure in people at high risk of
cardiovascular events [16] and
 Anticoagulation in people with atrial fibrillation [17].
We conducted semi-structured interviews with primary
care professionals based on the Theoretical Domains
Framework [18] to explore barriers and enablers to
achieving the above indicators. For each indicator, we
matched behaviour change techniques targeting clinicians
to the most salient barriers and enablers and embedded
them within intervention packages.
In brief, the audit and feedback component will com-
prise quarterly reports individualised for each practice
and presenting their performance against targeted clin-
ical indicators, together with motivational messages
based on key theoretical domains identified by our quali-
tative research. The educational outreach visits will be
delivered by trained pharmacist facilitators and involve
discussion of practice performance and development of
action plans. The computerised support will include
modified versions of the searches used to prepare the
audit reports and, for risky prescribing only, automated
messages triggered by potentially risky prescribing com-
binations. We will also offer practices up to 2 days of
additional pharmacist support. The nature of this sup-
port will be decided in discussion with practice but can
include review of patient notes or modification of com-
puterised searches to identify specific patient groups to
invite for consultation. All practices in the intervention
arms will be sent electronic and postal copies of the
feedback reports. They will also be offered educational
outreach, additional pharmacist support, searches to
identify patients and, where applicable, computerised
prompts. Given the pragmatic nature of these trials, the
acceptance and engagement with all components is op-
tional. We will further describe intervention develop-
ment and content in a separate paper.
Outcomes
The primary endpoints are as follows:
 The proportion of patients with type 2 diabetes
achieving all three of the following treatment
targets: blood pressure below 140/80 mmHg (or
130/80 mmHg if there is kidney, eye or
cerebrovascular damage), HbA1c value below or
equal to 59 mmol/mol and cholesterol level below
or equal to 5.0 mmol/l (trial 1)
 A composite measure of nine indicators of high-risk
NSAID and anti-platelet prescribing: prescribing a
traditional oral NSAID or low-dose aspirin in patients
with a history of peptic ulceration without
co-prescription of gastro-protection; prescribing a
traditional oral NSAID in patients aged 75 years or
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over without co-prescription of gastro-protection;
prescribing of a traditional oral NSAID and aspirin in
patients aged 65 years or over without co-prescription
of gastro-protection; prescribing of aspirin and
clopidogrel in patients aged 65 years or over
without co-prescription of gastro-protection;
prescribing of warfarin and a traditional oral
NSAID; prescribing of warfarin and low-dose
aspirin or clopidogrel without co-prescription of
gastro-protection; prescribing an oral NSAID in
patients with heart failure; prescribing an oral
NSAID in patients prescribed both a diuretic
and an angiotensin-converting-enzyme inhibitor
(ACE-I) or angiotensin receptor blocker (ARB)
and prescribing an oral NSAID in patients with
chronic kidney disease (CKD; trial 1)
 The proportion of patients with satisfactorily
controlled blood pressure according to
recommended targets: under 140/90 mmHg in
patients aged under 80 years with hypertension;
under 150/90 mmHg in patients aged 80 years and
over with hypertension; under 140/80 mmHg in
patients aged under 80 years with diabetes, under
130/80 mmHg if there are complications of diabetes;
under 130/80 mmHg in patients aged under
80 years with chronic kidney disease and
proteinuria; under 140/90 mmHg in patients aged
under 80 years with coronary heart disease; under
140/90 mmHg in patients aged under 80 years with
peripheral arterial disease; under 140/90 mmHg in
patients aged under 80 years with a history of stroke/
transient ischemic attack and under 140/90 mmHg in
patients aged under 80 years with a cardiovascular
disease risk of 20 % or higher (trial 2) and
 A composite of the proportion of men with atrial
fibrillation and a CHA2DS2-VASc score of 1
prescribed anticoagulation therapy and the
proportion of all people with atrial fibrillation and a
CHA2DS2-VASc score of 2 or above prescribed
anticoagulation therapy (trial 2).
Secondary endpoints comprise the following:
 The effects on separate individual indicators that
contribute to composite outcomes (e.g. individual
blood pressure, HbA1c and cholesterol targets in
patients with diabetes)
 The effects on recorded processes of care (the
proportion of patients with type 2 diabetes achieving
all nine of the following recommended processes of
care in the previous 12 months: blood pressure
recording, HbA1c recording, total cholesterol
recording, urine albumin to creatinine ratio (ACR)
or protein to creatinine ratio (PCR) or proteinuria
coding, estimated glomerular filtration rate (eGFR)
or serum creatinine testing, foot care review, retinal
screening, body mass index recording, smoking status)
 The effects on continuous intermediate clinical
outcomes (i.e. value of last recorded blood pressure,
HbA1c, cholesterol)
In addition, we will gather selected data from the
Quality and Outcomes Framework (QOF; 2015–2016
indicator list (Table 1). The QOF is a performance
management system whereby general practices are re-
munerated according to achievement of targets
reflecting quality of care across four domains of clin-
ical, organisational, patient experience and additional
services [19]. Practice data collection for QOF oper-
ates on an annual cyclical basis from 1 April to 31
March. Several indicators map onto our trial recom-
mendations (Table 1). We have also selected a series
of non-trial-related indicators that represent different
aspects of care and service delivery. These will be
used to measure unintended impacts on quality of
care and relate to four areas: coronary heart disease
(an example of a long-term physical condition),
mental health (long-term non-physical condition),
smoking (health promotion) and asthma (long-term
physical condition). All outcomes will be assessed at
1 year following randomisation.
Data collection
Primary and secondary endpoints
We will use anonymised patient health records, ex-
tracted remotely from participating practices to obtain
data on indicator adherence. The data will be col-
lected via the data quality team at the National
Health Service (NHS) Yorkshire & Humber Commis-
sioning Support Unit. Data extraction and collation
procedures are performed under the appropriate
Information Governance Guidance, in line with Caldi-
cott Principles.
Data queries are developed by mapping inclusion
and exclusion criteria to the numerators and denomi-
nators for each indicator and building the search
within SystmOne. Reports are generated by a data
analyst to define output for each indicator numerator
and denominator and extracted in a standardised for-
mat. The outputs are anonymised and checked for
accuracy prior to transfer to the Leeds Institute of
Clinical Trials Research (LICTR) via a secure file
transfer system.
Pre-intervention data will be extracted for randomisa-
tion stratification and then continue quarterly to inform
the content of feedback reports. The final extraction will
be used for endpoint analysis.
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Table 1 List of indicators from the Quality and Outcomes Framework 2015–2016 included in the ASPIRE analysis
Domain QOF indicator number
(2015–2016)
Indicator
Atrial fibrillation AF006 The percentage of patients with atrial fibrillation in whom stroke risk has been assessed
using the CHA2DS2-VASc score risk stratification scoring system in the preceding 12 months
(excluding those patients with a previous CHADS2 or CHA2DS2-VASc score of 2 or more).
Atrial fibrillation AF007 In those patients with atrial fibrillation with a record of a CHA2DS2-VASc score of 2 or more,
the percentage of patients who are currently treated with anticoagulation drug therapy.
Secondary prevention of
coronary heart disease
CHD002 The percentage of patients with coronary heart disease in whom the last blood pressure
reading (measured in the preceding 12 months) is 150/90 mmHg or less.
Secondary prevention of
coronary heart disease
CHD005 The percentage of patients with coronary heart disease with a record in the preceding
12 months that aspirin, an alternative anti-platelet therapy or an anti-coagulant is being taken.
Secondary prevention of
coronary heart disease
CHD007 The percentage of patients with coronary heart disease who have had influenza immunisation
in the preceding 1 August to 31 March.
Hypertension HYP006 The percentage of patients with hypertension in whom the last blood pressure reading
(measured in the preceding 12 months) is 150/90 mmHg or less.
Stroke and transient
ischemic attack
STIA003 The percentage of patients with a history of stroke or TIA in whom the last blood
pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less.
Diabetes mellitus DM002 The percentage of patients with diabetes, on the register, in whom the last
blood pressure reading (measured in the preceding 12 months) is 150/90 mmHg or less.
Diabetes mellitus DM003 The percentage of patients with diabetes, on the register, in whom the last blood pressure
reading (measured in the preceding 12 months) is 140/80 mmHg or less.
Diabetes mellitus DM004 The percentage of patients with diabetes, on the register, whose last measured
total cholesterol (measured within the preceding 12 months) is 5 mmol/l or less.
Diabetes mellitus DM006 The percentage of patients with diabetes, on the register, with a diagnosis of
nephropathy (clinical proteinuria) or micro-albuminuria who are currently
treated with ACE-I (or ARBs).
Diabetes mellitus DM007 The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is
59 mmol/mol or less in the preceding 12 months.
Diabetes mellitus DM008 The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is
64 mmol/mol or less in the preceding 12 months.
Diabetes mellitus DM009 The percentage of patients with diabetes, on the register, in whom the last IFCC-HbA1c is
75 mmol/mol or less in the preceding 12 months.
Diabetes mellitus DM0012 The percentage of patients with diabetes, on the register, with a record of a foot
examination and risk classification: (1) low risk (normal sensation, palpable pulses),
(2) increased risk (neuropathy or absent pulses), (3) high risk (neuropathy or absent
pulses plus deformity or skin changes in previous ulcer) or (4) ulcerated foot within
the preceding 12 months.
Diabetes mellitus DM0014 The percentage of patients newly diagnosed with diabetes, on the register, in preceding
1 April to 31 March who have a record of being referred to a structured education
programme within 9 months after entry on to the diabetes register
Diabetes mellitus DM0018 The percentage of patients with diabetes, on the register, who have had influenza
immunisation in the preceding 1 August to 31 March.
Mental health MH002 The percentage of patients with schizophrenia, bipolar affective disorder and other psychoses
who have a comprehensive care plan documented in the record, in the preceding 12 months,
agreed between individuals, their family and/or carers as appropriate.
Mental health MH003 The percentage of patients with schizophrenia, bipolar affective disorder and other
psychoses who have a record of blood pressure in the preceding 12 months.
Smoking SMOK002 The percentage of patients with any or any combination of the following conditions: coronary
heart disease (CHD), peripheral arterial disease (PAD), stroke or transient ischemic attack (TIA),
hypertension, diabetes, chronic obstructive pulmonary disease (COPD), chronic kidney disease
(CKD), asthma, schizophrenia, bipolar affective disorder or other psychoses whose notes record
smoking status in the preceding 12 months.
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Practice and patient characteristics
Data on practice characteristics will be obtained from
publicly available sources (http://www.hscic.gov.uk) and
include practice list size (number of registered patients),
number of general practitioner (GP) partners, number of
salaried GPs, practice teaching status, practice level
Index of Multiple Deprivation (IMD), ethnic profile of
practice register, achievement of QOF indicators, patient
satisfaction (proportion who would recommend practice
to others), patient-rated practice accessibility (proportion
able to speak with GP or nurse within 48 hours of
approach) and practice prescribing costs. Patient charac-
teristics will be extracted alongside adherence data and
include age, sex, co-morbidity (number of QOF disease
registers patient is included in) and polypharmacy (num-
ber of repeat prescriptions).
Intervention fidelity
Intervention delivery and fidelity will be monitored
throughout the trials. Structured logs record the number
of outreach sessions delivered, number of staff attending
and whether feedback reports were (i) received and (ii)
used, as well as any additional support requested by the
practice. Outreach facilitators will complete standard
review forms following each visit. Reasons for declining
an outreach visit will also be documented. We will col-
lect data on which practices accept the invitation to join
indicator-specific SystmOne organisational groups. Ac-
ceptance is required in order to access the searches, as
well as any available computer protocols. These lists will
be monitored during the trials and reminders sent to
practices which have not joined.
Sample size
Data collected for the second ASPIRE work package
(cross-sectional assessment in a random sample of prac-
tices of adherence to selected clinical indicators) was
used to estimate mean cluster size (number of targeted
patients per practice by indicator), coefficient of vari-
ation, intra-cluster correlation coefficient and control
group achievement rates (Table 2). Depending on the
recommendation, assumed intra-cluster correlation coef-
ficients (ICC) ranged from 0.03 to 0.06, mean cluster
sizes from 55 to 800 and the coefficient of variation of
cluster sizes from 0.6 to 0.79 (Table 2). The median effect
sizes on processes and outcomes of care for a range of sin-
gle interventions in guideline implementation studies are
around 4–9 % [20, 21]. Given the enhancements we are
making to the intervention packages and that we are tar-
geting recommendations with greater scope for improve-
ment [10], we judge that an estimated effect size of 15 %
for outcomes related to diabetes, hypertension and atrial
fibrillation are realistic and clinically relevant. Control
group adherence rates in risky prescribing are consider-
ably higher (Table 2), and considering a potential ceiling
effect, we estimated 5 % to be a realistic and clinically rele-
vant effect size for this intervention.
In order to achieve 90 % power, and allowing for an alpha
error rate of 2.5 % (to adjust for two outcome comparisons
in each trial) and a 10 % drop-out rate, we require 40 clus-
ters per arm in trial 1 (diabetes and risky prescribing) and
32 clusters per arm in trial 2 (hypertension and atrial fibril-
lation). We therefore aim to recruit 144 practices (Table 3).
We allowed for the possibility of a fifth arm because we an-
ticipated achieving above-target recruitment levels using
the opt-out approach.
Randomisation
Randomisation will be conducted using a computer-
generated minimisation programme (incorporating a
random element) to ensure arms are balanced. It will
follow a two-stage process. First, practices will be strati-
fied by CCG and practice list size (defined as above/
below the West Yorkshire median list size of 6562
patients) and then randomised to trial 1, trial 2 or the
no-intervention arm. Second, practices in trials 1 and 2
will then be stratified again by CCG, practice list size
and pre-intervention adherence to the two relevant tar-
geted clinical areas. They will then be randomised to the
individual arms within each trial. Cluster randomisation
will be performed at LICTR by the trial statistician.
For both trials, each practice will act as a control prac-
tice for the other corresponding arm in the trial to which
they are randomised. Practices in the no-intervention arm
will operate as additional controls.
Table 1 List of indicators from the Quality and Outcomes Framework 2015–2016 included in the ASPIRE analysis (Continued)
Smoking SMOK004 The percentage of patients aged 15 or over who are recorded as current smokers who have a
record of an offer or support and treatment within the preceding 24 months.
Smoking SMOK005 The percentage of patients with any or any combination of the following conditions: CHD, PAD,
stroke or TIA, hypertension, diabetes, COPD, CKD, asthma, schizophrenia, bipolar
affective disorder or other psychoses who are recorded as current
smokers who have a record of an offer of support and treatment
within the preceding 12 months
Asthma AST003 The percentage of patients with asthma, on the register, who have had an asthma
review in the preceding 12 months that includes an assessment of asthma control
using the three Royal College of Physician questions.
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General practice staff and trial personnel involved in
the delivery of the intervention will, of necessity, be
aware of assignment to allocation but collection of out-
comes for the primary endpoints will be blind.
Statistical analysis
All analyses and data summaries will be conducted on
the intention-to-treat (ITT) population, defined as all
randomised practices regardless of compliance with the
intervention or withdrawal from the study. No formal
interim analyses are planned, and final analysis will take
place when all available data are received from the final
extract.
Primary analysis
As the trials are cluster randomised, the primary out-
come measures (levels of adherence to the four indica-
tors) will be compared between the intervention and
control groups using two-level binary logistic models,
with patients nested within general practices. Effect sizes
and 95 % confidence intervals will be reported.
Secondary analyses
Secondary analyses will be undertaken using both binary
and continuous outcome data (e.g. blood pressure
levels). For binary outcome data, we will also be using
two-level binary logistic models, for continuous data,
two-level linear models. Effect sizes and 95 % confidence
intervals will be reported.
Cost-effectiveness analysis
We plan to conduct economic analyses for three of the
four intervention packages: diabetes control, risky pre-
scribing and blood pressure control. We had to limit the
number of outcomes modelled because of our limited
resources and selected three based on availability of
existing models.
Economic modelling has the primary objective of identi-
fying the interventions’ incremental cost-effectiveness ra-
tios. In order to assess the impact of the intervention over
a lifetime horizon, longer-term models will be developed
for each of the three selected areas. The decision analytic
models will be informed by published evidence on costs
(taking a UK health and social care perspective as per
NICE guidelines) and utility values (used to construct
quality-adjusted life years [QALYs]). Values generated for
time periods greater than 12 months will be discounted at
the 3.5 % rate.
The economic evaluations will make use of an adher-
ence parameter informed by effectiveness data obtained
from the study. The parameter will reflect the impact of
the intervention; for example, an improvement in adher-
ence should lead to an improvement in outcomes
(QALYs) predicted by the model.
The value of the intervention will depend upon the
value of the behaviour it promotes. Thus, its cost-
effectiveness will be application-specific, just as drugs
which treat multiple conditions do not have a single cost-
effectiveness. The main outcome of interest will be cost
per QALY and net monetary benefit. We will conduct
extensive deterministic sensitivity analysis and probabilis-
tic sensitivity analysis to assess uncertainty surrounding
estimates of cost-effectiveness.
Trial and data monitoring
Trial supervision includes a core project team, a Trial
Management Group (TMG; consisting of a subset of the
project team and relevant independent experts in statis-
tics and health economics) and an independent Trial
Steering Committee (TSC). For a trial of this nature and
duration, a separate Data Monitoring and Ethics Com-
mittee is not required. Rather, the TSC will adopt a
safety monitoring role, with the constitution of a sub-
committee to review safety issues where this becomes
necessary. Any clinical governance issues pertaining to
Table 2 Key sample size assumptions
Atrial fibrillation Blood pressure control Risky prescribing Diabetes control
Mean number of patients per practice (cluster size) 55 800 420 280
Coefficient of variation (CV) of cluster size 0.79 0.67 0.65 0.6
Intra-cluster correlation coefficient (ICC) 0.06 0.06 0.03 0.06
Control group adherence 0.6 0.72 0.89 0.43
Table 3 Trial design and number of practices required
Trial 1 Trial 2 Non-intervention control
Diabetes
control
Risky
prescribing
Blood pressure
control
Anticoagulation in atrial
fibrillation
40 40 32 32 [Number dependent on recruitment beyond that required for
intervention sample]
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aspects of routine management will be brought to the
attention of the TSC and, where applicable, to individual
practices.
Process evaluation
We will conduct a process evaluation alongside the trials
to:
 Describe how the intervention packages are
implemented and the extent to which they become
embedded in routine systems and practice
 Explore whether the interventions worked as
predicted or by an alternative means and
 Identify unintended consequences of the delivery
and implementation of the intervention packages in
practice.
Recruitment and consent
We will recruit a subset of general practices not involved
in the trials. Email invitations will be followed up by
telephone calls and practice-level informed consent ob-
tained. Practices will be reimbursed for their time and
commitment over the study period.
We aim to recruit eight practices, providing a sample
of two practices per clinical topic. We will purposively
select practices to ensure a spread across CCGs and a
range of practice sizes (patient list size and number of
practice staff ). Where individual practice staff members
participate in audio-recorded interviews, individual writ-
ten consent will be obtained.
Method
Process evaluation practices will be randomised by the
trial statistician to receive an intervention package tar-
geting one of the four indicators. These will be delivered
in identical fashion to, and in parallel with, the trial
practices.
In preparation for data collection at the process evalu-
ation practices, we will develop a logic model to capture
how we expect the intervention package and its constitu-
ent components to be received and how it may bring
about change [22, 23].
Throughout the intervention period, we will conduct in-
depth work with process evaluation practices to observe
and monitor how the interventions are received and im-
plemented. Data collection will proceed via observations,
interviews and the collection of administrative data [24].
 Observations: where possible, settings where
practice staff discuss or interact with the
intervention package and/or clinical topic will be
observed (e.g. educational outreach sessions,
practice meetings), and detailed field notes
generated to capture how staff receive and interact
with the intervention package at a group level [25].
No individual patient consultations or data will be
collected.
 Interviews: staff will be interviewed individually
about their role in the practice, their interaction
with the intervention, whether it is perceived to
influence behaviour in relation to the clinical topic,
if and how the intervention has been incorporated
into routine practice, and any unintended
consequences arising from the intervention.
Interviews will be both semi-structured and
open-ended to help capture intended and
unintended mechanisms. A range of practice staff
will be interviewed in each participating practice
(up to 12 individuals per site), including staff with
administrative, clinical and managerial roles. Interviews
will take place at three time points, twice to
coincide with delivery of key intervention
components (educational outreach and feedback
report delivery) and, finally, after trial end. Interviews
will be audio-recorded and transcribed verbatim.
 Administrative data: information relating to the
intervention package and/or target clinical
recommendations will be collected. Examples
include meeting minutes, practice protocols around
a clinical topic and communications (e.g. emails)
about the clinical topic or intervention package.
Analysis
Data will be collated to produce chronological recon-
structions of the process and outcomes of receiving and
implementing the intervention package. This will be on
a case by case basis, wherein each practice acts as a case
study [26]. Data will be analysed using a framework
approach [27] based on our pre-specified theories of
how the intervention package will work (outlined in the
logic model) and drawing on normalisation process the-
ory to understand the process of implementation in each
practice [28]. We also aim to identify and explore any
unintended consequences and mechanisms of the inter-
vention package during analysis.
Ethical review
Ethical approval has been obtained through the UK
National Research Ethics Service (14/SC/1393) (Additional
file 2). NHS Research and Development approvals were
granted by the NHS Yorkshire & Humber Commissioning
Support Unit on behalf of all the CCGs in West Yorkshire
(approved 30 January 2015).
Trial status
The trials are currently in progress. No endpoint data
collection nor cleaning has yet occurred.
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Discussion
The ASPIRE trials will provide robust evidence about
the effectiveness and cost-effectiveness of an implemen-
tation package for primary care targeting ‘high impact’
indicators, as well as the further insights generated by
the process evaluation.
Additional files
Additional file 1: CONSORT 2010 checklist of information to include
when reporting a cluster randomised trial. (DOCX 28 kb)
Additional file 2: Confirmation of ethical approval. (PDF 262 kb)
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